Dr. Schlomm received his MD at the Georg-August University Göttingen, Germany in 2001, and finished his habilitation thesis in 2009 at the University Medical Center Hamburg-Eppendorf. Dr. Schlomm was until early 2018 a faculty member and scientific director of the Martini-Clinic, Prostate Cancer Center at the University Medical Center Hamburg-Eppendorf (UKE). Currently he has taken over the chairman position of the urology department at the university medical center Charité Berlin.
Clinical validation of molecular markers are central topics of Dr. Schlomm’s research. In 2003, he established a prostate cancer biobank at the UKE, now consisting of over 20 000 prostate cancer samples, ready to use for molecular diagnostics. Together with Guido Sauter's group, Dr. Schlomm developed a prostate cancer TMA including over 17.000 fully annotated prostate cancers. Currently, he is expanding this platform towards other cancer entities in Berlin. At present, he is the clinical coordinator of the German ICGC (International Cancer Genome Consortium) and the TCGA (The Cancer Genome Atlas) prostate cancer genome sequencing projects.
Dr. Schlomm´s main collaboration partner of CCBIO is Prof. Karl-Henning Kalland. In 2017 Dr. Schlomm organized the Heinrich Warner Symposium, a biannual prostate cancer symposium in Hamburg, featuring international experts on prostate cancer biology, diagnosis and treatment. Dr. Kalland was among the invited speakers at the 2017 symposium. Together with Dr. Kallands group, Dr. Schlomm generated and tested several cancer biological hypotheses, was a consultant in grant applications to the Research Council of Norway and the Norwegian Cancer Society and is planning to collaborate in a immunotherapy based trial in 2018.